About InflaRx N.V.
https://www.inflarx.deInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.
CEO
Niels C. Riedemann
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 3
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:6.48M
Value:$6.94M
BANK OF AMERICA CORP /DE/
Shares:2.48M
Value:$2.65M
683 CAPITAL MANAGEMENT, LLC
Shares:2.25M
Value:$2.41M
Summary
Showing Top 3 of 33
About InflaRx N.V.
https://www.inflarx.deInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $23.83K ▼ | $9.5M ▼ | $-12.26M ▲ | -51.45K% ▼ | $-0.18 ▲ | $-12.13M ▲ |
| Q2-2025 | $39.43K ▲ | $10.56M ▼ | $-14.42M ▼ | -36.56K% ▼ | $-0.21 ▼ | $-14.21M ▼ |
| Q1-2025 | $0 ▲ | $13M ▲ | $-8.31M ▼ | 0% ▼ | $-0.13 ▼ | $-8.2M ▼ |
| Q4-2024 | $-423 ▼ | $6.94M ▼ | $-5.11M ▲ | 1.21M% ▲ | $-0.09 ▲ | $-5M ▲ |
| Q3-2024 | $123.82K | $15.56M | $-17.45M | -14.09K% | $-0.29 | $-17.33M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $44.65M ▼ | $65.16M ▼ | $19.79M ▲ | $45.37M ▼ |
| Q2-2025 | $48M ▼ | $73.44M ▼ | $16.4M ▼ | $57.04M ▼ |
| Q1-2025 | $65.86M ▲ | $87M ▲ | $16.53M ▲ | $70.47M ▲ |
| Q4-2024 | $18.38M ▼ | $76.02M ▼ | $14.6M ▲ | $61.42M ▼ |
| Q3-2024 | $26.21M | $79.69M | $14.41M | $65.28M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.26M ▲ | $-9.04M ▼ | $2.6M ▲ | $-84.95K ▲ | $-6.56M ▲ | $-9.13M ▼ |
| Q2-2025 | $-14.42M ▼ | $-7.55M ▲ | $-24.91M ▼ | $-99.58K ▼ | $-34.28M ▼ | $-7.57M ▲ |
| Q1-2025 | $-8.31M ▼ | $-14.02M ▼ | $17.66M ▲ | $27.01M ▲ | $28.91M ▲ | $-14.03M ▼ |
| Q4-2024 | $-5.11M ▲ | $-11.89M ▼ | $1.96M ▼ | $676.59K ▲ | $-7.83M ▼ | $-11.91M ▼ |
| Q3-2024 | $-17.45M | $-9.66M | $17.47M | $-97.09K | $7.05M | $-9.66M |
CEO
Niels C. Riedemann
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 2 of 3
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:6.48M
Value:$6.94M
BANK OF AMERICA CORP /DE/
Shares:2.48M
Value:$2.65M
683 CAPITAL MANAGEMENT, LLC
Shares:2.25M
Value:$2.41M
Summary
Showing Top 3 of 33